Investors fret as VBI's hep B vaccine fails key secondary PhIII study goal
Sobered by mounting costs, Dynavax $DVAX last month made the decision to focus all its resources on its 2017-approved hepatitis B vaccine Heplisav-B, which …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
